Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.31 |
| ▸ | METAP1 | P53582 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12043390 | 0.84 | ALDH1A1 (0.34) | CYP1A2CYP2A6METAP1ALDH1A1GAA | |
| SCHEMBL276962 | 0.78 | — | — | |
| SCHEMBL10426767 | 0.76 | MAPT (0.40) | ALDH1A1GAAMAPT | |
| SCHEMBL5644783 | 0.76 | CA1 (0.31) | ACHEPARP1PARP10 | |
| SCHEMBL547264 | 0.76 | ESR2 (0.46) | ALDH1A1MAPTHSD17B10 | |
| SCHEMBL5537608 | 0.76 | — | — | |
| SCHEMBL2011445 | 0.76 | — | — | |
| SCHEMBL13911575 | 0.76 | ALDH1A1 (0.34) | ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL2722706 | 0.72 | PNMT (0.39) | CYP2A6 | |
| SCHEMBL2003995 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3582783-B1 | 7-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | TREVENA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-4086249-A2 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | Trevena, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| US-20170210725-A1 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | TREVENA, INC. | 2017-07-27 | — | — | US | disclosed |
| WO-2017040545-A1 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | TREVENA, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| US-8283368-B2 | Selective ligands for the dopamine 3 (D3) receptor and methods of using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283368-B2 | Selective ligands for the dopamine 3 (D3) receptor and methods of using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-09 | — | — | US | disclosed |
| US-20110319362-A1 | STAT3 LIGANDS AND THERAPEUTIC USES THEREOF | WANG SHAOMENG (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319362-A1 | STAT3 LIGANDS AND THERAPEUTIC USES THEREOF | WANG SHAOMENG (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110184033-A1 | Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110184033-A1 | Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-28 | — | — | US | disclosed |
| WO-2010077589-A2 | STAT3 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN OFFICE OF TECHNOLOGY TRANSFER (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010025235-A1 | SELECTIVE LIGANDS FOR THE DOPAMINE 3 (D3) RECEPTOR AND METHODS OF USING THE SAME | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
| EP-1345930-A2 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002050067-A2 | PHARMACEUTICAL HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
| EP-0230941-B1 | PHOTOPOLYMERISABLE COMPOSITION AND PHOTOPOLYMERISABLE REGISTRATION MATERIAL CONTAINING IT | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-09-09 | — | — | EP | disclosed |
| EP-0363776-A2 | Light-sensitive composition and light-sensitive copy material produced therewith | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-04-18 | — | — | EP | disclosed |
| US-4780393-A | POLYMERIC BINDER, TERMINAL ETHYLENIC COMPOUND, PHOTOINITIATOR, LEVCO BASE OF TRIARYLMETHANE DYE AND PHOTOC ROMIC SPIRO-INDOLINO-BENZOPYRAN COMPOUND | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-10-25 | — | — | US | disclosed |
| EP-0230941-A2 | Photopolymerisable composition and photopolymerisable registration material containing it | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210725-A1 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | OPRD1, OPRM1, OPRK1 | CYP1A2 686/4885CYP2A6 384/4885METAP1 2886/4885 |
| US-20110184033-A1 | Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same | DRD3, HTR3C, HTR3A | CYP1A2 1924/4885CYP2A6 1059/4885METAP1 1555/4885 |
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | CYP1A2 48/4885CYP2A6 39/4885METAP1 1627/4885 |
| US-20110319362-A1 | STAT3 LIGANDS AND THERAPEUTIC USES THEREOF | STAT3, JAK2, STAT6 | CYP1A2 4602/4885CYP2A6 3967/4885METAP1 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.